TipRanks
Advertisement
Advertisement
Candel Therapeutics Adds Independent Director to Board
PremiumCompany AnnouncementsCandel Therapeutics Adds Independent Director to Board
21d ago
Candel Therapeutics Highlights Progress of Lead Oncology Candidate
Premium
Company Announcements
Candel Therapeutics Highlights Progress of Lead Oncology Candidate
22d ago
Candel Therapeutics price target raised to $12 from $9 at BofA
Premium
The Fly
Candel Therapeutics price target raised to $12 from $9 at BofA
2M ago
Candel Therapeutics publishes pivotal Phase 3 data for Aglatimagene
PremiumThe FlyCandel Therapeutics publishes pivotal Phase 3 data for Aglatimagene
4M ago
Candel Therapeutics price target raised to $9 from $7 at BofA
Premium
The Fly
Candel Therapeutics price target raised to $9 from $7 at BofA
5M ago
Candel Therapeutics Highlights Phase 3 Prostate Cancer Data
Premium
Company Announcements
Candel Therapeutics Highlights Phase 3 Prostate Cancer Data
5M ago
Candel Therapeutics: Strengthened Balance Sheet and Late‑Stage Pipeline Catalysts Support High‑Risk Buy Rating Despite Dilution
PremiumRatingsCandel Therapeutics: Strengthened Balance Sheet and Late‑Stage Pipeline Catalysts Support High‑Risk Buy Rating Despite Dilution
7M ago
Candel Therapeutics price target lowered to $22 from $24 at Citi
Premium
The Fly
Candel Therapeutics price target lowered to $22 from $24 at Citi
7M ago
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
Premium
Company Announcements
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
7M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―